We are in a new era of medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. Yet despite so much promise, progress isn’t certain. Our commitment to research and development is crucial to sustaining innovation and continuing its progress.
Since peaking in 1991, the death rate associated with cancer declined by 29%, which translates to 2.9 million fewer cancer deaths.
After decades of helping to lower the mortality rate from pneumonia, tuberculosis and other types of infection, the medicines we rely on now face the growing threat of antimicrobial resistance.
Innovation does not happen in a vacuum. Instead, it requires a rich ecosystem of talent, capital, expertise and logistics to translate theoretical science into life-saving treatments and therapies.
We are on the cusp of a major, positive disruption in the U.S. health care system due in part to the exponential growth in clinical data, advent and incorporation of artificial intelligence and the increasing realignment of the health care sector.
Experts and thought leaders touching every aspect of cancer came together for "Future Shapers: A New Era in Cancer Care", a conversation led by Axios and part of PhRMA's GoBoldly Campaign.
A neuroscientist and neuropathologist by training, Dan is responsible for development across all of Lilly's products - from clinical trials through approvals - specifically working within the areas of oncology, diabetes, Alzheimer's disease, immunology and pain management.